MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2016 International Congress

    GAITRite comparison between Parkinson’s disease stages

    W. Deeb, D. Martinez-Ramirez, J. Giugni, M. Okun, C. Hass (Gainesville, FL, USA)

    Objective: To compare gait performance across Parkinson's disease stages. Background: Parkinson's disease (PD) is characterized with changes in locomotion and posture, which are associated with…
  • 2016 International Congress

    Gender and age-based differential item functioning (DIF) analysis of MDS-UPDRS

    C.G. Goetz, L. Wang, G.T. Stebbins, B.C. Tilley, S. Luo (Chicago, IL, USA)

    Objective: Test if DIF due to gender or age is present in MDS-UPDRS items. Background: Testing a rating scale for DIF is a core step…
  • 2016 International Congress

    Home care program for patients with Parkinson’s disease – A Singapore experience

    H.L. Ng, W. Li, S. Abdul Karim, K.Y. Tay, W.L. Au, L.C.S. Tan (Singapore, Singapore)

    Objective: To review the disease profile of patients who were enrolled in the Home Care Program and evaluate the outcomes of the program. Background: With…
  • 2016 International Congress

    Successful treatment of movement disorders after resection of midbrain cavernous malformations: Report of two cases

    A. Smolanka, V. Smolanka, K. Karpinska, M. Dovhanych, T. Havryliv (Uzhhorod, Ukraine)

    Objective: To evaluate the treatment of movement disorders which presented as a consequence of haemorrhage from midbrain cavernous malformations. Background: Few cases of movement disorders…
  • 2016 International Congress

    Engrailed enhances dopamine synthesis in healthy dopaminergic neurons

    D. Alvarez-Fischer, M. Baaske, F. Vulinovic, J. Fuchs, P. Seibler, A. Rakovic, A. Prochiantz, C. Klein (Lübeck, Germany)

    Objective: The aim of the present study was to further elucidate the role of Engrailed in dopamine neurotransmission. Background: Engrailed1 and Engrailed2, collectively Engrailed, are…
  • 2016 International Congress

    Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

    C. Mahapatra, R. Manchanda (Mumbai, India)

    Objective: Understanding the drug effects with respect to various ion channels on subthalamic nucleus (STN) cells is the key to safety pharmacology assessment. Here our…
  • 2016 International Congress

    Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, E. Valadez, Y. Torres-Yaghi, R. Falconer, R. Mills, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

    Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…
  • 2016 International Congress

    Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry

    W. Poewe, T. Kimber, B. Bermans, P. Odin, A. Antonini, O. Bajenaru, K. Onuk, A. Yegin, L. Bergmann, K.R. Chaudhuri (Innsbruck, Austria)

    Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…
  • 2016 International Congress

    Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

    S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

    Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…
  • 2016 International Congress

    Taking specialist clinics into community nursing homes

    T. Williams, S. Mahon, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

    Objective: Evaluate the effectiveness of delivering specialist Parkinson's care in community care home settings. Background: Our drive to improve older people's care has led to…
  • « Previous Page
  • 1
  • …
  • 373
  • 374
  • 375
  • 376
  • 377
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley